I fase III- forsøgene DUET- 1 og DUET- 2 var de mutationer, som oftest blev udviklet hos patienter med virologisk svigt over for INTELENCE- regimet V108I, V179F, V179I, Y181C og Y181I, som normalt opstod sammen med flere andre NNRTI- resistensassocierede mutationer (RAM).
In the Phase III trials DUET-1 and DUET-2, mutations that developed most commonly in patients with virologic failure to the INTELENCE containing regimen were V108I, V179F, V179I, Y181C and Y181I, which usually emerged in a background of multiple other NNRTI resistance-associated mutations (RAMs).